Other TRIUMPH Trials Additional Phase 3 trials in the TRIUMPH program are ongoing: TRIUMPH-1: Retatrutide in obesity (general population), results expected 2026 TRIUMPH-2: Retatrutide in type 2 diabetes, results expected 2026 TRIUMPH-3: Retatrutide cardiovascular outcomes trial, results expected 2027 Visualize Your Retatrutide Journey See how retatrutide builds up in your system over time and compare different dosing protocols
Constipation and abdominal discomfort are also reported, though rates decline as the body adapts
Patients will need protein-rich meals and resistance exercise to stay strong
Digestive side effects, blood sugar changes, hydration status and nutrition intake should be considered before changing treatment
If you use a sleep-tracking watch, it can highlight some signs of a sleep disorder
While this evidence in adults is promising, further research is warranted to specifically evaluate the potential role and efficacy of L-carnitine in modulating inflammation and oxidative stress related to bacterial infections in pediatric populations, particularly where mitochondrial dysfunction may play a key role